Evidence map›Paper›PMID 32009414›Full record

ArticleOrganic letters2020

Regioselective Synthesis of a

Yu Li, Zachary M Sandusky, Rajender Vemula, Qi Zhang, Bulan Wu, Shinji Fukuda, Mingzong Li, Deborah A Lannigan, George A O'Doherty

Abstract read
In one paragraph

Article in Organic letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Therapeutic targeting of p90 ribosomal S6 kinase.Frontiers in cell and developmental biology · 2023
    Review
  4. Chemical communications (Cambridge, England) · 2022
    Review
  5. Identifying requirements for RSK2 specific inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu LiDepartment of Chemistry and Chemical Biology , Northeastern University , Boston , Massachusetts 02115 , United States.
Zachary M SanduskyDepartment of Pathology, Microbiology & Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Rajender VemulaDepartment of Chemistry and Chemical Biology , Northeastern University , Boston , Massachusetts 02115 , United States.ORCID 0000-0002-7214-1094
Qi ZhangDepartment of Chemistry and Chemical Biology , Northeastern University , Boston , Massachusetts 02115 , United States.
Bulan WuDivision of Natural Sciences, College of Natural & Applied Sciences , University of Guam , Mangilao , Guam 96923.ORCID 0000-0001-5084-6352
Shinji FukudaDepartment of Pathology, Microbiology & Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.ORCID 0000-0002-6920-1818
Mingzong LiDepartment of Chemistry and Chemical Biology , Northeastern University , Boston , Massachusetts 02115 , United States.
Deborah A LanniganDepartment of Pathology, Microbiology & Immunology , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
George A O'DohertyDepartment of Chemistry and Chemical Biology , Northeastern University , Boston , Massachusetts 02115 , United States.ORCID 0000-0002-1699-2249

Funding

RSK2 in Estrogen Receptor Positive (ER+) Breast CancerR01CA213201 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LANNIGAN, DEBORAH, SULIKOWSKI, GARY ALLEN · 2018 to 2022
$1.8M
Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogensR21AI142040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$476k
Fusidic acid derivatization to enhance entry into Gram-negative pathogensR21AI146485 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$475k
Targeted modification of the apramycin 2-deoxystreptamine ring to block aminoglycoside modifying enzyme-based inactivation and enhance potency against multidrug-resistant Gram-negative pathogensR03AI144196 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$183k
NCI NIH HHS R01 CA213201NIAID NIH HHS R03 AI144196NIAID NIH HHS R21 AI142040NIAID NIH HHS R21 AI146485
6 · The paper itself

Abstract

An asymmetric synthesis of two analogues of SL0101 (

Indexed as

BenzopyransMolecular StructureMonosaccharidesProtein Kinase InhibitorsRibosomal Protein S6 Kinases, 90-kDaStereoisomerismBenzopyransMonosaccharidesProtein Kinase InhibitorsRibosomal Protein S6 Kinases, 90-kDaSL0101

Identifiers

PMID32009414
PMCPMC7292201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.